S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
NASDAQ:AXSM

Axsome Therapeutics - AXSM Stock Forecast, Price & News

$46.27
+0.95 (+2.10%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$45.12
$47.12
50-Day Range
$21.74
$48.36
52-Week Range
$19.38
$48.82
Volume
603,193 shs
Average Volume
839,697 shs
Market Capitalization
$1.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.63

Axsome Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
95.9% Upside
$90.63 Price Target
Short Interest
Bearish
18.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.58mentions of Axsome Therapeutics in the last 14 days
Based on 27 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.22) to ($2.17) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

405th out of 1,135 stocks

Pharmaceutical Preparations Industry

203rd out of 557 stocks

AXSM stock logo

About Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics Trading Up 2.1 %

NASDAQ:AXSM traded up $0.95 on Friday, hitting $46.27. 603,193 shares of the stock were exchanged, compared to its average volume of 839,697. The company has a debt-to-equity ratio of 6.15, a quick ratio of 3.54 and a current ratio of 2.44. The company's 50-day moving average price is $36.27 and its 200 day moving average price is $33.69. Axsome Therapeutics has a 52 week low of $19.38 and a 52 week high of $48.82.

Axsome Therapeutics (NASDAQ:AXSM - Get Rating) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($1.06) EPS for the quarter, beating analysts' consensus estimates of ($1.19) by $0.13. During the same period in the prior year, the firm earned ($0.86) earnings per share. On average, equities research analysts forecast that Axsome Therapeutics will post -4.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on AXSM shares. Morgan Stanley lifted their price target on Axsome Therapeutics from $54.00 to $55.00 and gave the company an "equal weight" rating in a report on Wednesday. Cowen lifted their price target on Axsome Therapeutics from $120.00 to $130.00 and gave the company an "outperform" rating in a report on Wednesday, June 29th. Cantor Fitzgerald cut their price target on Axsome Therapeutics from $64.00 to $54.00 in a report on Wednesday. Cowen lifted their price target on Axsome Therapeutics from $120.00 to $130.00 and gave the company an "outperform" rating in a report on Wednesday, June 29th. Finally, Mizuho cut their price target on Axsome Therapeutics from $51.00 to $49.00 in a report on Tuesday, May 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Axsome Therapeutics has an average rating of "Moderate Buy" and an average target price of $90.63.

Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Stock News Headlines

Axsome Therapeutics Whale Trades For August 12
Axsome Therapeutics (NASDAQ:AXSM) Trading Down 3.4%
Axsome: One Step At A Time
2 Biotechs That Recently Soared -- Are They Buys?
See More Headlines
Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Company Calendar

Last Earnings
8/09/2022
Today
8/14/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXSM
Employees
108
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$90.63
High Stock Price Forecast
$180.00
Low Stock Price Forecast
$49.00
Forecasted Upside/Downside
+95.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-130,400,000.00
Pretax Margin
-1,699.89%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.39 per share

Miscellaneous

Free Float
28,796,000
Market Cap
$1.80 billion
Optionable
Optionable
Beta
1.92

Key Executives

  • Dr. Herriot Tabuteau M.D. (Age 54)
    Founder, Chairman, CEO & Pres
    Comp: $1.06M
  • Mr. Nick Pizzie CPA (Age 47)
    M.B.A., Chief Financial Officer
    Comp: $553.97k
  • Mr. Mark L. Jacobson (Age 39)
    COO & Sec.
    Comp: $554.72k
  • Mr. Hunter Murdock Esq.
    Exec. VP of Legal & Compliance
  • Dr. Amanda Jones Pharm.D. (Age 39)
    Sr. VP of Clinical Devel.
  • Ms. Lori Englebert M.B.A. (Age 44)
    Exec. VP of Commercial & Bus. Devel.
  • Mr. Kevin Laliberte Pharm.D. (Age 44)
    Exec. VP of Product Strategy
  • Joseph Debrah-Afful CPA
    M.B.A., Director of Fin.













AXSM Stock - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXSM shares.
View AXSM analyst ratings
or view top-rated stocks.

What is Axsome Therapeutics' stock price forecast for 2022?

9 equities research analysts have issued twelve-month target prices for Axsome Therapeutics' shares. Their AXSM share price forecasts range from $49.00 to $180.00. On average, they anticipate the company's share price to reach $90.63 in the next twelve months. This suggests a possible upside of 95.9% from the stock's current price.
View analysts price targets for AXSM
or view top-rated stocks among Wall Street analysts.

How have AXSM shares performed in 2022?

Axsome Therapeutics' stock was trading at $37.78 on January 1st, 2022. Since then, AXSM shares have increased by 22.5% and is now trading at $46.27.
View the best growth stocks for 2022 here
.

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AXSM earnings forecast
.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced its quarterly earnings results on Tuesday, August, 9th. The company reported ($1.06) EPS for the quarter, beating analysts' consensus estimates of ($1.19) by $0.13. During the same period last year, the company posted ($0.86) earnings per share.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Iridian Asset Management LLC CT (1.40%), Ikarian Capital LLC (0.00%), Group One Trading L.P. (0.00%), Pictet Asset Management SA (0.91%), Northern Trust Corp (0.72%) and US Bancorp DE (0.68%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends
.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $46.27.

How much money does Axsome Therapeutics make?

Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $1.80 billion. The company earns $-130,400,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis.

How many employees does Axsome Therapeutics have?

The company employs 108 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.

This page (NASDAQ:AXSM) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.